Xencor (NASDAQ:XNCR – Get Free Report)‘s stock had its “outperform” rating reissued by equities researchers at Wedbush in a research report issued on Wednesday, Benzinga reports. They currently have a $30.00 price target on the biopharmaceutical company’s stock. Wedbush‘s price target suggests a potential upside of 19.55% from the company’s current price.
A number of other analysts have also recently commented on XNCR. JPMorgan Chase & Co. lifted their price target on Xencor from $14.00 to $21.00 and gave the stock a “neutral” rating in a research report on Thursday, September 3rd. Raymond James Financial lifted their price target on Xencor from $40.00 to $46.00 and gave the stock a “strong-buy” rating in a research report on Tuesday, September 1st. Truist Financial reaffirmed a “buy” rating and set a $29.00 price target (up from $27.00) on shares of Xencor in a research report on Monday, September 28th. Bank of America lifted their price objective on Xencor from $20.00 to $26.00 and gave the company a “neutral” rating in a research note on Monday, September 21st. Finally, Wells Fargo & Company began coverage on Xencor in a research note on Wednesday, September 30th. They set an “overweight” rating and a $55.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Xencor currently has a consensus rating of “Moderate Buy” and a consensus price target of $34.00.
Read Our Latest Report on XNCR
Xencor Stock Up 0.6%
Shares of Xencor stock traded up $0.16 during trading on Wednesday, reaching $25.10. The company’s stock had a trading volume of 217,455 shares, compared to its average volume of 987,547. The company has a market cap of $1.87 billion, a price-to-earnings ratio of -11.55 and a beta of 0.89. Xencor has a 1-year low of $10.38 and a 1-year high of $30.61. The company has a 50-day simple moving average of $25.24 and a two-hundred day simple moving average of $18.16.
Xencor (NASDAQ:XNCR – Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.80) by $0.51. The firm had revenue of $51.22 million during the quarter, compared to analysts’ expectations of $18.89 million. Xencor had a negative return on equity of 28.66% and a negative net margin of 155.59%. The business’s quarterly revenue was up 17.4% on a year-over-year basis. During the same quarter last year, the firm earned ($0.41) EPS. As a group, analysts anticipate that Xencor will post -3.05 earnings per share for the current year.
Institutional Trading of Xencor
Institutional investors and hedge funds have recently made changes to their positions in the business. Integrated Wealth Concepts LLC purchased a new stake in shares of Xencor in the second quarter valued at approximately $30,000. Allworth Financial LP purchased a new stake in Xencor during the 2nd quarter worth approximately $55,000. GAMMA Investing LLC increased its stake in Xencor by 15.5% during the 3rd quarter. GAMMA Investing LLC now owns 4,269 shares of the biopharmaceutical company’s stock worth $107,000 after buying an additional 572 shares in the last quarter. EP Wealth Advisors LLC purchased a new stake in Xencor during the 2nd quarter worth approximately $218,000. Finally, AXQ Capital LP purchased a new stake in Xencor during the 2nd quarter worth approximately $261,000.
About Xencor
Xencor, Inc is a clinical-stage biopharmaceutical company headquartered in Monrovia, California. Founded in 1997, the company develops engineered antibodies and other biologic medicines for the treatment of cancer, autoimmune disorders and other serious diseases.
Xencor’s research is centered on its XmAb technology platform, which is designed to modify antibodies to improve their therapeutic properties or create new antibody-based mechanisms. The platform supports the development of bispecific antibodies, immune-cell engagers and antibodies with extended activity in the body.
Recommended Stories
- Five stocks we like better than Xencor
- 2 Steel Giants Just Reported Earnings—and Told Very Different Stories
- Swiping to Record Highs: Why Visa Remains a Fortress
- Salesforce Fuels AI Engine With $5.66B Braze Buyout
- ServiceNow Orchestrates AI’s Next Act—Can Earnings Deliver?
Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.
